Plecanatide

Gut Health / GI

Also known as: Trulance

Guanylate Cyclase-C AgonistsResearch phase: FDA-approved, post-marketingRegulatory: FDA-approved (2017, Trulance) for chronic idiopathic constipation and IBS-C.

Mechanism

Similar to linaclotide — an oral peptide for chronic constipation and IBS-C. It's designed to mimic uroguanylin, a natural gut hormone that's activated by the pH of your intestines. It may cause less diarrhea than linaclotide because it activates more specifically in the right part of the gut.

Technical detail

Sixteen-amino acid synthetic analog of uroguanylin with single amino acid substitution (Asp3→Glu3) for stability. Like linaclotide, activates GC-C on intestinal epithelium, increasing cGMP-mediated fluid secretion via CFTR. Key differentiator: pH-dependent activation — more active in acidic proximal duodenum (pH 5) than in neutral/basic distal intestine, mimicking uroguanylin's natural activation profile. This may reduce distal-colon fluid secretion (less diarrhea). Phase 3 trials showed significant improvement in CSBM frequency and abdominal discomfort.

Effects

## Gastrointestinal System [Tier 1 - FDA-Approved, Phase III Human Data] - 16-amino-acid synthetic analog of uroguanylin, an endogenous intestinal peptide - Activates guanylate cyclase-C (GC-C) receptors in a pH-dependent manner — activated preferentially at pH 5.0-6.0 (proximal duodenum/jejunum) rather than throughout the entire intestine - This pH-dependent activation may result in more physiological fluid secretion patterns vs. linaclotide - Increases intracellular cGMP → CFTR chloride channel activation → intestinal fluid secretion and accelerated transit - FDA-approved for IBS-C and chronic idiopathic constipation ## Visceral Pain [Tier 1 - Human Data] - Like linaclotide, extracellular cGMP reduces visceral hypersensitivity by desensitizing colonic nociceptors - Abdominal pain improvement demonstrated in Phase III IBS-C trials - Pain reduction onset may be slightly faster than linaclotide (possibly due to pH-targeted activation in proximal gut) ## Systemic [Tier 1 - Human Data] - Negligible systemic absorption — acts locally in the intestinal lumen - No clinically meaningful drug interactions - No hepatic or renal dose adjustment needed

Practitioner Guide

## Clinical Positioning Plecanatide (Trulance) is the second GC-C agonist approved for IBS-C and CIC. Its key differentiator from linaclotide is pH-dependent activation — it is designed to mimic uroguanylin's physiological activation profile, which may result in slightly less diarrhea. ## Prescribing - IBS-C: 3mg oral once daily - CIC: 3mg oral once daily - Single dose strength (3mg tablets) — no titration needed - Take with or without food (unlike linaclotide, which requires fasting) ## Practical Advantages Over Linaclotide - No fasting requirement — can be taken with breakfast (major compliance advantage) - Possibly lower diarrhea rate (though head-to-head data are limited) - Single dose strength simplifies prescribing - pH-dependent activation may cause less proximal small intestinal fluid secretion ## Patient Selection - Similar to linaclotide: IBS-C and CIC patients, especially with abdominal pain component - Patients who cannot reliably take medication on empty stomach → prefer plecanatide - Patients who had diarrhea on linaclotide → try plecanatide (may be better tolerated) - Pediatric patients under 6: contraindicated (same as linaclotide) ## In Peptide Therapy Context - Same considerations as linaclotide: mainstream pharmaceutical, useful adjunct for IBS-C in peptide therapy patients - Particularly relevant for GLP-1 agonist-induced constipation management

Dosing Protocols

chronic_constipationbasic tier
Dose
3000mcg
Frequency
Once daily
Timing
Take with or without food; swallow tablet whole or crush and mix with applesauce or water for administration via nasogastric tube
Route
oral
Cycle
4-52 weeks

FDA-approved (Trulance) 3mg for CIC and IBS-C. Plecanatide is a 16-amino-acid analog of uroguanylin that activates GC-C in a pH-dependent manner, preferentially in the proximal intestine where pH is lower. This pH-dependent activation may produce fewer diarrhea side effects vs. linaclotide. Same downstream mechanism: cGMP-mediated chloride/bicarbonate secretion via CFTR. Single dose for all indications; no titration needed. Continuous use.

Contraindications & Cautions

  • hard stop — Children under 6 years of age
    BLACK BOX WARNING: Plecanatide (Trulance) is contraindicated in children under 6 years of age. Same class risk as linaclotide — fatal dehydration in neonatal mice from severe diarrhea.
    Action: Absolutely contraindicated. Do not use in children under 6. Black box warning.
  • hard stop — Children 6-17 years of age
    Plecanatide should be avoided in pediatric patients 6-17 per black box warning.
    Action: Avoid use. Not recommended for patients 6-17.
  • hard stop — Mechanical GI obstruction
    Contraindicated with known or suspected mechanical GI obstruction. Increased intestinal secretion behind obstruction is dangerous.
    Action: Do not use. Rule out obstruction first. Labeled contraindication.
  • hard stop — Pregnancy
    No adequate human data during pregnancy. Minimal systemic absorption expected but safety not established.
    Action: Do not use during pregnancy without physician approval.
  • caution — Severe diarrhea
    Plecanatide may cause or worsen diarrhea. Risk of dehydration and electrolyte imbalance.
    Action: Monitor hydration. Discontinue if severe diarrhea develops.

Evidence

Research Summary

## Tier 1 — Phase III/FDA-Approved Human Data - Phase III IBS-C trials: plecanatide 3mg improved abdominal pain, CSBM frequency, and stool consistency vs. placebo at 12 weeks - Phase III CIC trials: similar improvements in bowel function endpoints - Diarrhea rate: ~5% (potentially lower than linaclotide's 16-20%, though not directly compared in same trial) - Overall adverse event profile similar to placebo; discontinuation for diarrhea <2% ## Tier 2 — Mechanistic Data - pH-dependent GC-C activation confirmed: plecanatide is 10x more potent at pH 5.0 than pH 7.0 - Uroguanylin analog design means it mimics the natural duodenal response to acid exposure - cGMP-mediated visceral analgesia mechanism same as linaclotide ## Tier 3 — Preclinical - Uroguanylin knockout mice show altered intestinal fluid homeostasis and increased susceptibility to colorectal tumors - pH-dependent activation localizes fluid secretion to the proximal gut, potentially reducing watery diarrhea from distal colonic secretion ## Evidence Gaps - No head-to-head trial vs. linaclotide (the most important missing study) - Long-term efficacy and safety data limited compared to linaclotide - Specific data on use with GLP-1 agonists not available

Build a personalized protocol with Plecanatide →